Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 1, 1996, Pages 31-37

  Grasser, A ^a   Moller A ^a   Backmund, H ^a   Yassouridis, A ^a   Holsboer, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

CRH; Dexamethasone; HPA system; Multiple sclerosis

Indexed keywords

CORTICOSTEROID RECEPTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE COURSE; ENDOCRINE SYSTEM; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL;

EID: 0030027673     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211419     Document Type: Article

References (50)

1. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. American Psychiatric Press, Washington DC, 1987
2. Anderson DK, Dugan LL, Means ED, Horrocks LA: Methylprednisolone and membrane properties of primary cultures of mouse spinal cord. Brain Res 637: 119-125, 1994
3. Antoni FA: Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14: 76-122, 1993
4. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupfersmith MJ, Paty DW, Brown CH, The Optic Neuritis Study Group: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329: 1764-1769, 1993
5. Bernard CAA, de Rosbo NK: Multiple sclerosis: an autoimmune disease of multifactorial origin. Curr Opin Immunol 4: 760-765, 1992
6. Bilezikjian VM, Blunt AL, Vale WW: The cellular actions of vasopressin in corticotrophs of the anterior pituitary: resistance to glucocorticoid actions. Mol Endocrinol 1: 451-458, 1987
7. Bolton C, Flower RJ: The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci 45: 97-104, 1989
8. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson J-A, Van der Saag PT: Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9: 401-412, 1995
9. Cazzullo CL, Piotti LE, Montarini R, Montalbetti N, Bonini PA, Marforio S: Pituitary adrenocortical function in multiple sclerosis. Life Sci 17: 137-144, 1968
10. Ebers GC: Treatment of multiple sclerosis. Lancet 343: 275-279, 1994
11. Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, Scheinberg LC: A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 49: 238-244, 1992
12. Gillies G, Lowry PJ: Corticotropin releasing factor may be modulated by vasopressin. Nature 278: 463-464, 1979
13. Hamilton M: Development of a rating scale for primary depressive illness. Br J Consult Clin Psychol 6: 278-296, 1967
14. Heuser I, Wark HJ, Keul J, Holsboer F: Hypothalamic-pituitary-adrenal-axis function in elderly endurance athletes. J Clin Endocrinol Metab 73: 485-488, 1991
15. Heuser I, Yassouridis A, Holsboer F: The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356, 1994
16. Holsboer F, Stalla GK, von Bardeleben U, Hammann K, Müller H, Müller OA: Acute adreaocortical stimulation by recombinant gamma interferon in human controls. Life Sci 42: 1-5, 1988
17. Holsboer F, Lauer CJ, Schreiber W, Krieg JC: Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62: 340-347, 1995
18. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V: Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course. J Psychiat Res 28: 381-299, 1994
19. Ketelacr CJ, Delmotte P: Results of adrenal and pituitary stimulation tests in patients with multiple sclerosis. Acta Neurol Scand 48: 467-478, 1972
20. Klapps P, Seyfert S, Fischer T, Scherbaum WA: Endocrine function in multiple sclerosis. Acta Neurol Scand 85: 353-357, 1992
21. Kupersmith MJ, Kaufmann D, Paty DW, Ebers G, McFarland H, Johnson K, Reingold S, Whitaker J: Megadose corticosteroids in multiple sclerosis. Neurology 44: 1-4, 1994
22. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452, 1983
23. Lorr M, Klett CJ: Inpatient Multidimensional Psychiatric Scale (IMPS), revised. Consulting Psychologists Press, Palo Alto CA, 1967
24. MacPhee IAM, Antoni FA, Mason DW: Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 169: 431-445, 1989
25. Maida E, Summer K: Serum cortisol levels of multiple sclerosis patients during ACTH treatment. J Neurol 220: 143-148, 1979
26. Mason D: Genetic variation in the stress response: susceptibility to experimental allergic encephalomyelitis and implications for human inflammatory disease. Immunol Today 12: 57-60, 1991
27. Mason D, MacPhee I, Antoni F: The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 70: 1-5, 1990
28. Michelson D, Stone L, Galliven E, Magiakon MA, Chrousos GP, Sternberg EM, Gold PW: Multiple sclerosis associated with alterations in HPA axis function. J Clin Endocrinol Metab 79: 848-853, 1994
29. Millac P, Cook DB, Chase K: Endocrine function in multiple sclerosis. J Neurol Neurosurg Psychiatry 32: 414-418, 1969
30. Nolten WE, Goldstein D, Lindstrom M, McKenna MV, Carlson IH, Trump DL, Schiller J, Borden EC, Ehrlich EN: Effects of cytokines on the pituitary-adrenal axis in cancer patients. J Interferon Res 13: 349-357, 1993
31. Ormerod IEC, Miller DH, McDonald WI, du Boulay EPGH, Rudge P, Kendall BE, Moseley IF, Johnson G, Tofts PS, Halliday AM, Bronstein AM, Scaravilli F, Harding AE, Barnes D, Zilkha KJ: The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. Brain 110: 1579-1616, 1987
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtelotte WW: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231, 1983
33. Purba JS, Raadsheer FC, Hofman MA, Ravid R, Polman CH, Kamphorst W, Swaab DF: Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology 62: 62-70, 1995
34. Reder AT, Lowy MT, Meltzer HY, Antel JP: Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 37: 849-853, 1987
35. Reder AT, Makowiec RL, Lowy MT: Adrenal size is increased in multiple sclerosis. Arch Neurol 51: 151-154, 1994
36. Reul JMHM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F: Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60: 509-519, 1994
37. Schobitz B, Reul JMHM, Holsboer F: The role of the hypothalamic-pituitary-adrenocortical system during infection and inflammation. Crit Rev Neurobiol 8: 263-291, 1994a
38. Schobitz B, Sutanto W, Carey MP, Holsboer F, de Kloet ER: Endotoxin and interleukin 1 decreases the affinity of hippocampal mineralocorticoid (type I) receptor in parallel to activation of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology 60: 124-133, 1994b
39. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg J-C: Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology, in press
40. Solomon S: Corticostatins. Trends Endocrinol 4: 260-264, 1993
41. Stein M, Schleifer SJ, Keller SE: Psychoimmunology in clinical psychiatry. In: Hales RE, Frances LJ (eds) Annual review of psychiatry: neuroscience techniques in clinical psychiatry. American Psychiatric Press, Washington, DC, pp 210-234, 1987
42. Sternberg EM, Young WS, Bernardini R, Calogero AE, Chrousos GP, Gold PW, Wilder RL: A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 86: 4771-4775, 1989
43. Teasdale GM, Smith PA, Wilkinson R, Latner A, Miller H: Endocrine activity in multiple sclerosis. Lancet 1: 64-68, 1967
44. Trapp T, Rupprecht R, Castrén M, Reul JMHM, Holsboer F: Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the central nervous system. Neuron 13: 1457-1462, 1994
45. von Bardeleben U, Holsboer F, Stalla GK, Müller OA: Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 37: 1613-1618, 1985
46. von Bardeleben U, Holsboer F: Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1: 485-488, 1989
47. von Bardeleben U, Holsboer F: Effect of age upon the cortisol response to human CRH in depressed patients pretreated with dexamethasone. Biol Psychiatry 29: 1042-1050, 1991
48. Warren S, Greenhill S, Warren KG: Emotional stress and the development of multiple sclerosis; case control evidence of a relationship. J Chronic Dis 32: 821-831, 1982
49. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C: Animal models. Ann Neurol 36: S47-S53, 1994
50. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK: Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. JAMA 269: 2232-2238, 1993